Journal of Young Pharmacists logo
Submit
Journal of Young PharmacistsACADEMIC PUBLISHING
Review

Bedaquiline e The first ATP synthase inhibitor against multi drug resistant tuberculosis

1★, 1★ Corresponding author

  1. 1Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry 605006, INDIA.

CORRESPONDENCE

Mageshwaran Lakshmanan

Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry 605006, INDIA.

waranmagesh87@gmail.com

Received: 06-11-2013; Revised: 03-12-2013; Accepted: 30-12-2013.

Volume 5, Issue 4 · pp. 112-115 · 2013 · DOI: 10.1016/j.jyp.2013.12.002

ABSTRACT

Increasing incidence of MDR-TB, long duration of treatment and co-infection with HIV are the significant problems in achieving the eradication of tuberculosis. Bedaquiline is an anti-tuberculosis drug with unique mechanism of action. It selectively inhibits the mycobacterial energy metabolism i.e. ATP synthesis and found to be effective against all states of Mycobacterium tuberculosis like active, dormant, replicating, non-replicating, intracellular and extracellular. Preclinical studies have shown the efficacy of bedaquiline in terms of reduction in bacterial load and treatment duration. Phase II clinical studies have established the safety, tolerability and earlier sputum conversion time in patients with MDR-TB. In 2012 FDA approved bedaquiline for treatment of MDR-TB and XDR-TB.

KEYWORDS

Open in new tab

REFERENCES

As published

Showing references and in-text citations exactly as published.

    Cite this article

    SELECT FORMAT

    Lakshmanan, M., & Xavier, A. S. (2013). Bedaquiline e The first ATP synthase inhibitor against multi drug resistant tuberculosis. Journal of Young Pharmacists, 5(4), 112-115. https://doi.org/10.1016/j.jyp.2013.12.002

    Copyright and licence

    © 2013 Author(s)

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. CC BY-NC-SA 4.0